



ATTORNEYS AT LAW

1840 DUKE STREET
ALEXANDRIA, VIRGINIA 22314
USA(703) 413-3000
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW
AND RELATED FEDERAL AND ITC LITIGATION

WWW.OBLON.COM

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

TO	Examiner Fronda	March 4, 2004
NAME	USPTO	DATE
COMPANY/FIRM		571-273-0929
NUMBER OF PAGES INCLUDING COVER:	10	FAX #
		CONFIRM FAX: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
FROM	Daniel J. Pereira, Ph.D.	211223US0X
NAME	703 412-6560	OUR REFERENCE
DIRECT PHONE #		09/938,540
		YOUR REFERENCE

MESSAGE

Attached is a copy of the Amendment filed February 26, 2004.

Handwritten signature and text: "Reg. # 45,544"

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

DOCKET NO: 211223US0X

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
BETTINA MOECKEL, ET AL. : EXAMINER: FRONDA, CHRISTIAN L.
SERIAL NO: 09/938,540 :
FILED: AUGUST 27, 2001 : GROUP ART UNIT: 1652
FOR: NEW NUCLEOTIDE SEQUENCES :
WHICH CODE FOR THE CCPA1 GENE

AMENDMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated August 26, 2003, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.